DS-1093 + placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anaemia
Conditions
Anaemia
Trial Timeline
May 1, 2014 → Feb 1, 2015
NCT ID
NCT02142400About DS-1093 + placebo
DS-1093 + placebo is a phase 1 stage product being developed by Daiichi Sankyo for Anaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02142400. Target conditions include Anaemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02142400 | Phase 1 | Completed |
Competing Products
11 competing products in Anaemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Hetrombopag Olamine Tablet | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Hetrombopag Olamine Tablet | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Neorecormon | Roche | Approved | 85 |
| SAR445088 | Sanofi | Phase 1 | 32 |
| BIVV020 | Sanofi | Phase 1 | 32 |
| G-CSF + Early retreatment with ATG | Sanofi | Phase 3 | 76 |
| rilzabrutinib + placebo | Sanofi | Phase 3 | 76 |
| Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia) + MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland) | Sandoz Group | Phase 3 | 74 |
| Ferric Maltol | Medpace | Phase 1 | 30 |
| IV trivalent saccharose hydroxide ferrous + Oral ferrous fumarate + Oral and intravenous Placebo | Rafael Holdings | Approved | 77 |